J&J Reorganizes Consumer Group - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

J&J Reorganizes Consumer Group


ePT--the Electronic Newsletter of Pharmaceutical Technology

On Apr. 4, Johnson & Johnson instituted a new structure for its Consumer Group. The group now includes a Global Franchise Organization that consists of four consumer categories: skin care for babies and adults, over-the-counter (OTC) medicines, oral care and topical health, and women’s and intimate health, according to a Reuters report. Research and development will be among the Global Franchise Organization’s activities.

The company created four regional divisions for North America, Asia–Pacific and Europe, the Middle East, and Africa and Latin America. The divisions will market J&J’s various consumer product lines, with the exception of the North America region. The latter division will market all product lines except OTC medicines sold in the United States. A new US OTC business headed by Pat Mutchler will market those products, according to Reuters. In addition, Marc Robinson, head of J&J’s consumer-healthcare businesses, and Peter Luther, president of McNeil, will be given new assignments, according to Reuters.

J&J told employees of the organizational changes in an internal company memo in February 2011, according to Reuters. In the memo, the company said that the regional and franchise structure would enable quick reactions to changing market conditions and the efficient execution of regionwide initiatives, while accelerating growth in emerging markets, according to Reuters.

On Mar. 10, 2011, FDA filed a consent decree against McNeil, a subsidiary of J&J, for failing to comply with current good manufacturing practice requirements. The consent decree prevents McNeil from manufacturing and distributing drugs from its Fort Washington, Pennsylvania, facility until FDA determines that its operations comply with the law. The facility manufactured OTC products, including children’s Tylenol, Motrin, Zyrtec, and Benadryl products.

In addition, the decree requires McNeil to destroy all drugs that have been recalled from the Fort Washington; Las Piedras, Puerto Rico; and Lancaster, Pennsylvania; facilities since December 2009. McNeil must retain an independent expert to inspect the facilities and evaluate whether the violations have been corrected.

See related Pharm Tech articles:

FDA Files Consent Decree against Johnson & Johnson (ePT)

Consent Decree (Finally) for J&J (blog post)

J&J Recalls Yet More Medicines (PT Europe)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here